- Home
- NEGG vs CHRS Comparison
NEGG vs CHRS Comparison
Compare NEGG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CHRS
- Stock Information
- Founded
- NEGG 2001
- CHRS 2010
- Country
- NEGG United States
- CHRS United States
- Employees
- NEGG N/A
- CHRS N/A
- Industry
- NEGG Other Specialty Stores
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- CHRS Health Care
- Exchange
- NEGG Nasdaq
- CHRS Nasdaq
- Market Cap
- NEGG 122.3M
- CHRS 159.2M
- IPO Year
- NEGG 2010
- CHRS 2014
- Fundamental
- Price
- NEGG $43.46
- CHRS $1.28
- Analyst Decision
- NEGG
- CHRS Strong Buy
- Analyst Count
- NEGG 0
- CHRS 4
- Target Price
- NEGG N/A
- CHRS $4.51
- AVG Volume (30 Days)
- NEGG 2.1M
- CHRS 1.3M
- Earning Date
- NEGG 08-29-2025
- CHRS 11-05-2025
- Dividend Yield
- NEGG N/A
- CHRS N/A
- EPS Growth
- NEGG N/A
- CHRS N/A
- EPS
- NEGG N/A
- CHRS 1.55
- Revenue
- NEGG $1,313,127,000.00
- CHRS $272,209,000.00
- Revenue This Year
- NEGG N/A
- CHRS N/A
- Revenue Next Year
- NEGG N/A
- CHRS $109.48
- P/E Ratio
- NEGG N/A
- CHRS $2.52
- Revenue Growth
- NEGG N/A
- CHRS 52.33
- 52 Week Low
- NEGG $3.32
- CHRS $0.66
- 52 Week High
- NEGG $137.84
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NEGG 44.92
- CHRS 60.48
- Support Level
- NEGG $33.52
- CHRS $1.26
- Resistance Level
- NEGG $48.15
- CHRS $1.40
- Average True Range (ATR)
- NEGG 8.89
- CHRS 0.08
- MACD
- NEGG -2.69
- CHRS -0.00
- Stochastic Oscillator
- NEGG 27.27
- CHRS 59.68
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.